With advancements in cancer treatment offering new hope, the NHS in England is rolling out a revolutionary 60-second immunotherapy jab, pembrolizumab (Keytruda), potentially saving over 100,000 hours of staff time annually and drastically reducing patient treatment times. This rapid administration aims to allow patients more time to live their lives outside of hospital and frees up crucial clinic capacity. This new injectable form replaces the previous intravenous (IV) infusion, which could take up to two hours, and is now available for 14 different types of cancer, including lung, breast, head and neck, and cervical cancers. The treatment works by blocking the PD-1 protein, which inhibits the immune system’s ability to attack cancer cells, thereby empowering the immune system to recognize and combat them. This innovation is part of a broader trend in cancer care, with immunotherapy and CAR T-cell therapies showing significant promise in extending survival for aggressive cancers, and liquid biopsies enabling earlier detection. Early results from the NEOPRISM-CRC study, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, indicate that a similar immunotherapy (pembrolizumab) given as a pre-surgical “head start” has kept patients with stage two or three colorectal cancer cancer-free for nearly three years, challenging the traditional approach of surgery followed by chemotherapy.
In the realm of kidney disease, the landscape is also rapidly evolving. In the US, the National Kidney Foundation (NKF) has recognized Vertex with the 2026 Kidney Biotech Innovation Award for their “true disease-modifying innovation” in kidney disease treatment, signifying a move beyond mere symptom management. Promising new treatments are emerging for chronic kidney disease (CKD), with medications like SGLT2 inhibitors (e.g., empagliflozin and dapagliflozin) and GLP-1 receptor agonists (e.g., semaglutide and tirzepatide) showing significant benefits in slowing disease progression, reducing protein in the urine, and lowering cardiovascular risk. For instance, semaglutide (Ozempic) has received FDA approval for reducing the risk of kidney disease progression, kidney failure, and cardiovascular death in patients with type 2 diabetes and CKD. Furthermore, new therapies are being investigated for rare kidney diseases, with iptacopan showing promise in slowing the loss of kidney function in patients with IgA nephropathy. The advancements extend to transplantations, with the FDA clearing an investigational xenokidney clinical trial using gene-edited pigs, potentially expanding the availability of organs for patients with end-stage renal disease.
Regarding heart health, new minimally invasive procedures are transforming cardiac care. Loma Linda University Health has become the first non-trial hospital on the West Coast to perform a mitral valve replacement using a newly FDA-approved transcatheter mitral valve system, allowing the valve to be replaced through a leg vein and avoiding open-heart surgery entirely. This offers a less invasive alternative for patients, especially older or medically fragile individuals who may not be candidates for traditional surgery. Innovations in heart valve technology continue, with advancements in transcatheter aortic valve replacement (TAVR) and the development of devices for mitral and tricuspid valve positions. Stanford researchers are also developing lab-grown “mini-hearts” with functional blood vessels for improved drug testing and regenerative medicine approaches aimed at helping the heart repair itself after injury. A recent study published in JAMA Cardiology highlights that adults with prediabetes and hypertension who also have subclinical heart injury or stress face a significantly increased risk of heart failure, underscoring the importance of identifying and managing these overlapping risk factors.
In diabetes management, the focus is on enhanced technology and more convenient treatment options. Next-generation Continuous Glucose Monitoring (CGM) devices are becoming more accurate, discreet, and longer-lasting, providing real-time data to smartphones and smartwatches, and alerting users to dangerous hypoglycemic events. Smart insulin delivery systems, or “closed-loop” systems, are acting as artificial pancreases, automatically adjusting insulin doses based on real-time CGM data. The wider availability of once-weekly insulins is also reducing the burden of daily injections for patients. Furthermore, the American Diabetes Association’s (ADA) 2026 Standards of Care have broadened CGM eligibility to include all individuals on insulin or non-insulin therapies where it aids management, and have removed prerequisites for automated insulin delivery (AID) initiation, streamlining access to these technologies. Predictive AI modeling is also showing potential for earlier identification of Type 1 diabetes, allowing for timely education and support before complications arise.
The area of liver disease is seeing advancements in treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), often linked to obesity and type 2 diabetes. Drugs originally developed for type 2 diabetes, such as GLP-1 receptor agonists (e.g., semaglutide) and SGLT2 inhibitors, are demonstrating significant benefits beyond blood sugar control, including resolving liver inflammation and reducing liver fat. Resmetirom has received regulatory approval for the treatment of non-cirrhotic MASH, showing the ability to improve liver inflammation and fibrosis. For chronic hepatitis D virus (HDV) infection, Hepcludex (bulevirtide) is awaiting FDA approval as the first treatment for this condition in the US, offering hope for patients with limited therapeutic options.
